Page 86 - தொற்று நோய்கள் சமூகம் ஆஃப் அமெரிக்கா News Today : Breaking News, Live Updates & Top Stories | Vimarsana

By Peter Loftus Johnson & Johnson s Covid-19 vaccine was authorized for use in the U.S. by federal health regulators in late February and supplies of doses are ramping up. It is the third shot to be cleared after vaccines from Pfizer Inc. and its partner BioNTech SE and from Moderna Inc. And it is the first shot requiring just one dose, rather than two. Here s what we know and don t know: How do the three Covid-19 vaccines compare? They all work well, health experts say. The Pfizer-BioNTech and Moderna shots were more than 94% effective at preventing Covid-19 in their late-stage trials, while J&J s effectiveness was 66%. But the difference may be less than it seems. The Pfizer-BioNTech and Moderna shots were tested before the emergence of strains like one first identified in South Africa, which various studies have indicated eludes vaccines somewhat, though they still work against it. J&J s vaccine was tested in South Africa, and its effectiveness wasn t as high there

South africaUnited statesPeter loftusJohnson covidPfizer incEmergent biosolutions incDrug administrationModerna incInfectious diseases society of americaGregory polandMayo clinicInfectious diseases societyLatin americaDow jonesஒன்றுபட்டது மாநிலங்களில்பீட்டர் லோஃப்டஸ்